Clinical Report: Assessment of Perampanel's Effectiveness in Pediatric Epilepsy

Overview

This study evaluates the efficacy and safety of perampanel as initial monotherapy in pediatric patients with newly diagnosed epilepsy. Results indicate a significant seizure-free rate and manageable adverse events over a 12-month follow-up period.

Background

Perampanel is an antiseizure medication with a unique mechanism of action, making it a potential option for pediatric epilepsy treatment. Understanding its effectiveness and safety profile is crucial, especially as current guidelines favor other medications as first-line treatments. This study contributes valuable data to the ongoing evaluation of perampanel's role in pediatric epilepsy management.

Data Highlights

Key Findings

• Seizure-free rate at 12 months was 64.1% among 128 patients.
• Seizure-free rate for patients with self-limited epilepsy with centrotemporal spikes (SeLECTS) was 78.6%.
• The average adverse events (AEs) rate was 24.8%, with dizziness being the most common AE.
• 5.1% of patients discontinued PER due to intolerable AEs.
• Higher seizure-free rates were observed in patients receiving 4 mg/day of PER (70.3%).

Clinical Implications

Perampanel demonstrates promising efficacy as an initial treatment for pediatric epilepsy, particularly in specific subgroups like SeLECTS. Clinicians should monitor for adverse events, which are generally mild and manageable, allowing for continued treatment through dose adjustments.

Conclusion

This study supports the use of perampanel as an effective and safe initial monotherapy for pediatric patients with newly diagnosed epilepsy, warranting further consideration in clinical practice.

Related Resources & Content

1. Frontiers in Neurology, 2026 -- Perampanel use in pediatric autoimmune encephalitis-related seizures and epilepsy: a retrospective case series
2. Drugs - Real World Outcomes, 2022 -- Long-Term Use of Stiripentol in Pediatric and Adult Patients with Drug-Resistant Epilepsies: A Retrospective Analysis of 196 Cases Assessing Efficacy and Safety
3. Drugs - Real World Outcomes, 2016 -- Monitoring Adverse Drug Reactions in Inpatients Treated with Newer Antiepileptic Medications Through Systematic Analysis of Routine Clinical Data
4. Intensive Care Medicine, 2012 -- Incidence and Outcomes of Seizures in 204 Unconscious Pediatric Patients
5. NICE, 2025 -- Treating epileptic seizures in children, young people and adults
6. 5 Treating epileptic seizures in children, young people and adults | Epilepsies in children, young people and adults | Guidance | NICE
7. Checking your browser - reCAPTCHA
8. • Elderly: Increase dose no more frequently than every 2 weeks (2.6)